The contractor shall provide preclinical development support for candidate products and drug development activities. The scope of work encompasses activities that range from initial product…
Active Awarded Last action
- Contract number
- 75N93021D00001
- Awardee
-
Sri International UEI SRG2J1WS9X63
- Awarding agency
-
National Institute of Allergy and Infectious Diseases
National Institutes of Health, Department of Health and Human Services
- Task orders
- 3 $855,783 obligated
Award facts
- Opportunity
-
- Preclinical Services for HIV Therapeutics Pre-Solicitation · 75N93019R00021 · Posted Oct 4, 2019
- Preclinical Services for HIV Therapeutics Award Notice · Posted Oct 20, 2020
- Preclinical Services for HIV Therapeutics Solicitation · Posted Dec 5, 2019
- Combined order value
- $855,783 Current and potential, with all options
- Last date to order 86% complete
- IDV ceiling 1% used
- $107,274,471.00
- Award type
- Multiple award
- Who can order
- Only the awarding agency
- NAICS code
- 541715 Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)
- Set-aside
- No set-aside
- Competition
- Full and Open Competition · 3 offers Negotiated Proposal / Quote
- Pricing
- Cost Plus Fixed Fee
- Legislative mandates
-
- Employment Eligibility Verification (E-Verify) FAR subpart 22.18
- Service Contract Inventory FAR subpart 4.17
Award details come from SAM.gov/FPDS.
About this IDV
The National Institute of Allergy and Infectious Diseases awarded an indefinite-delivery, multiple-award contract to Sri International on October 15, 2020, with a ceiling of $107.3 million for preclinical development support for HIV therapeutics, concluding October 14, 2027.
The IDIQ encompasses preclinical services ranging from initial product discovery through activities supporting clinical trials and product licensure across seven task areas: in vitro testing, synthesis of therapeutic agents, small animal models for HIV/HBV/HCV and mycobacterium, formulation development and clinical dosage manufacturing, preclinical pharmacology and toxicology, and an infectious-disease reagent program. Task Area B (synthesis of therapeutic agents) carried a small-business set-aside under NAICS 541715 with a 1,000-employee size standard; the broader IDIQ used no set-aside. The original solicitation anticipated 6–21 task orders annually across all task areas, valued at approximately $500,000 to $5 million each.
Place of performance is Menlo Park, California. The contract runs five years base plus two-year option period.
Recent task-order activity under this IDIQ includes a delivery order issued September 30, 2025, for pharmacokinetics research on long-acting antitubercular drug preparations in rodents, ceiling $830,604, cost-plus-fixed-fee, completing January 31, 2027. An April 2021 delivery order funded development of a quality assurance/quality control plan and task-order initiation activities, ceiling $24,546.26. An October 2020 delivery order funded the guaranteed minimum amount at $0 ceiling.
Description
The contractor shall provide preclinical development support for candidate products and drug development activities. The scope of work encompasses activities that range from initial product discovery to those required to support clinical trials and/o
Task orders
Transactions
| Action | Obligated | Date |
|---|---|---|
| Other Administrative Action | $0 | |
| Other Administrative Action | $0 | |
| Other Administrative Action | $0 | |
| Other Administrative Action | $0 | |
| Other Administrative Action | $0 | |
| Other Administrative Action | $0 | |
| Original award | $0 |
Quick answers
Who was awarded contract 75N93021D00001?
75N93021D00001 was awarded to Sri International by National Institute of Allergy and Infectious Diseases (National Institutes of Health) on October 15, 2020.
How much is contract 75N93021D00001 worth?
Orders under 75N93021D00001 have obligated $855,783. 75N93021D00001's own ceiling is $107,274,471.
How many orders have been placed under contract 75N93021D00001?
3 orders have been placed under 75N93021D00001, the latest on September 30, 2025.
Who can order from contract 75N93021D00001?
75N93021D00001 is a multiple award indefinite delivery contract. Only the awarding agency can place orders on it.
Is contract 75N93021D00001 part of a contract vehicle?
Yes. 75N93021D00001 is part of Preclinical Services for HIV Therapeutics.
Was contract 75N93021D00001 competed?
The extent of competition for 75N93021D00001 was full and open competition. The government received 3 offers.
On GovTribe
See this IDV's full record
- Every order and transaction
- The awardee's other awards and teaming partners
- Similar IDVs and recompete opportunities
- Ask GovTribe AI about this IDV